Clinical Trial Update: A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Participants With Transfusion-Dependent β-Thalassemia [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating LentiGlobin BB305 for transfusion-dependent beta-thalassemia has completed with results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Beta-thalassemia

Drugs mentioned

• LentiGlobin BB305

Snippet

Sponsor: Genetix Biotherapeutics Inc. | Conditions: Beta-Thalassemia | Phase 3 | Status: COMPLETED | Results posted: 2023-12-29